Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-05-29

Clinical Trial Update: MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas [Phase 1, Phase 2]

View source ↗

Summary

The study evaluates pembrolizumab in combination with MRI-guided laser ablation for recurrent malignant gliomas, with Phase 1/2 results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Malignant Glioma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-05-29